Short-term effects and safety of a natural oral supplement containing glucosinolates, phytosterols, and citrus flavonoids compared with hormone treatment for the management of postmenopausal symptomatic women: a pilot single-center randomized phase 2 clinical trial
article
OA: green
CC0
Abstract
OBJECTIVE: This study aimed to evaluate the short-term efficacy and safety of an oral herbal supplement containing glucosinolates, phytosterols, and citrus flavonoids for menopausal symptoms in comparison with estrogen plus progestogen therapy (EPT) among postmenopausal women. METHODS: This was a pilot single-blinded, three-armed phase II randomized clinical trial, controlled with EPT. Sixty participants were randomly assigned to receive treatment for 3 months: (1) an oral herbal supplement of 1,500 mg/d (G1, n = 20), (2) an oral herbal supplement of 3,000 mg/d (G2, n = 20), or (3) conjugated equine estrogens 0.625 mg/d plus medroxyprogesterone acetate of 5 mg/d (EPT group, n = 20). The primary endpoint was the intensity of menopausal symptoms as measured using the Menopause-Specific Quality of Life Questionnaire (global and domain scores). The Menopause-Specific Quality of Life Questionnaire uses a 7-point scale to rate the symptom intensity, with higher scores indicating severity. The secondary endpoints were hormonal, lipid, and safety profiles. RESULTS: Fifty-four participants (n = 54) completed the study. The mean, model-estimated, and global menopausal symptom scores at 3 months were 85.8 in the EPT group, 61.3 in G1, and 62.5 in G2. Participants treated with the herbal compound had lower global (13.7 [6.9-20.4], P < 0.001) and physical symptom scores (6.6 [1.6-11.5], P = 0.002) on the second month and lower psychosocial symptom scores (3.8 [1.3 to 6.3], P < 0.001) on the third month of follow-up, compared with EPT. Conversely, participants receiving EPT showed better outcomes on vasomotor symptoms since the first month of treatment (-6.1 [-8.3 to -4.0], P < 0.001). The EPT group exhibited higher values of estradiol and lower follicle-stimulating hormone and luteinizing hormone since the first month of follow-up. Also, total cholesterol, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol were significantly higher in this group than in G2. CONCLUSIONS: In this small single-blind exploratory trial, the oral herbal supplement was more efficacious in reducing global, physical, and psychosocial menopausal symptoms in the short term than EPT. However, further studies are needed to adequately assess the efficacy and safety of this herbal supplement in the treatment of menopausal symptoms.
My notes (saved in your browser only)
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
References (69)
- doi:10.1039/c7tx00184c via openalex
- doi:10.1016/j.ecl.2015.05.001 via openalex
- doi:10.7326/m14-0353 via openalex
- doi:10.3390/molecules191221442 via openalex
- doi:10.1089/jwh.2012.3719 via openalex
- doi:10.1001/jama.288.7.872 via openalex
- W180752123 via openalex
- doi:10.3892/etm.2014.1923 via openalex
- doi:10.1016/j.pbb.2012.08.017 via openalex
- doi:10.1016/j.numecd.2014.04.013 via openalex
- doi:10.5001/omj.2015.34 via openalex
- doi:10.1016/j.maturitas.2013.11.001 via openalex
- doi:10.1186/1746-4269-6-30 via openalex
- doi:10.1016/j.maturitas.2016.02.015 via openalex
- doi:10.3945/ajcn.115.124545 via openalex
- doi:10.1002/14651858.cd009672.pub2 via openalex
- doi:10.1046/j.1471-4159.2003.01652.x via openalex
- doi:10.19082/5826 via openalex
- doi:10.5740/jaoacint.sgeramprasath via openalex
- W2135329990 via openalex
- W2183021014 via openalex
- W2475767983 via openalex
- doi:10.1136/bmj.39555.441944.be via openalex
- doi:10.3390/nu9121320 via openalex
- doi:10.1210/jc.2015-3767 via openalex
- doi:10.1016/j.ejphar.2012.11.003 via openalex
- doi:10.1016/j.pnpbp.2012.09.003 via openalex
- doi:10.1016/j.ejphar.2008.03.021 via openalex
- doi:10.1016/j.maturitas.2011.07.017 via openalex
- doi:10.1016/j.jneuroim.2017.11.006 via openalex
- doi:10.1016/j.ajog.2006.05.056 via openalex
- W2989282449 via openalex
- W3025722642 via openalex
- doi:10.1155/2019/5484138 via openalex
- doi:10.1080/13697137.2018.1540565 via openalex
- doi:10.1017/s0007114518000600 via openalex
- doi:10.2147/ijwh.s158913 via openalex
- doi:10.1080/09513590.2020.1821639 via openalex
- doi:10.1080/13697137.2020.1851183 via openalex
- doi:10.3389/fphar.2020.599959 via openalex
- doi:10.1016/j.cbi.2022.110117 via openalex
- doi:10.1038/s41574-022-00685-4 via openalex
- doi:10.1016/j.bpobgyn.2021.09.012 via openalex
- doi:10.1210/endrev/bnab011 via openalex
- doi:10.3390/biom11121825 via openalex
- W6600050674 via openalex
- W6839276666 via openalex
- doi:10.2147/ijwh.s365808 via openalex
- doi:10.1371/journal.pmed.1003731 via openalex
- doi:10.1177/17407745231160074 via openalex
- doi:10.1016/j.phyplu.2022.100326 via openalex
- doi:10.1146/annurev-nutr-071715-050718 via openalex
- doi:10.7314/apjcp.2012.13.2.427 via openalex
- doi:10.7326/0003-4819-133-6-200009190-00014 via openalex
- doi:10.1161/jaha.120.017416 via openalex
- doi:10.1093/humupd/dmm012 via openalex
- doi:10.3389/fphar.2021.767975 via openalex
- doi:10.1080/09513590.2021.1960965 via openalex
- doi:10.1016/j.foodchem.2019.02.071 via openalex
- doi:10.1001/jama.2016.8012 via openalex
- doi:10.1002/mnfr.201500379 via openalex
- doi:10.1007/s12272-020-01292-5 via openalex
- doi:10.59566/ijbs.2005.1033 via openalex
- doi:10.1016/j.maturitas.2008.07.002 via openalex
- doi:10.1089/jmf.2021.0054 via openalex
- doi:10.1097/mol.0b013e32835c07fd via openalex
- doi:10.3390/medicina55090559 via openalex
- doi:10.5935/abc.20170158 via openalex
- doi:10.1016/j.atherosclerosis.2016.01.035 via openalex
Source provenance
- openalex
- last seen: 2026-05-11T04:31:57.718481+00:00
License: CC0
· commercial use OK